Synapse - Works

Results (22057)

Efficacy and safety of pembrolizumab (pembro; MK-3475) for patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC) enrolled in KEYNOTE-001

Meeting Abstract

Soria, J. C.; Flotten, O.; Horn, L.; Felip, E.; Gandhi, L.; Hui, R.; Hellmann, M.; Leighl, N.; Zhang, J.; Kondic, A.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save

Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearrangements

Meeting Abstract

Siena, S.; Drilon, A. E.; Ou, I. S. H.; Farago, A. F.; Patel, M.; Bauer, T. M.; Hong, D.; Liu, S. V.; Lee, J.; Patel, R.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save

Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210)

Meeting Abstract

Rosenberg, J.; Petrylak, D.; Abidoye, O.; Van der Heijden, M. S.; Hofman-Censits, J.; Necchi, A.; O'Donnell, P. H.; Balmanoukian, A.; Loriot, Y.; Retz, M.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save

Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC)

Meeting Abstract

Pietanza, M. C.; Spigel, D.; Bauer, T. M.; Ready, N. E.; Glisson, B. S.; Morgensztern, D.; Robert, F.; Salgia, R.; Kochendorfer, M.; Patel, M.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save

Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial

Meeting Abstract

Choueiri, T.; Escudier, B.; Powles, T.; Mainwaring, P.; Rini, B.; Donskov, F.; Hammers, H.; Hutson, T.; Roth, B.; Peltola, K.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save

CheckMate 025: A randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)

Meeting Abstract

Sharma, P.; Escudier, B.; McDermott, D. F.; George, S.; Hammers, H. J.; Srinivas, S.; Tykodi, S. S.; Sosman, J. A.; Procopio, G.; Plimack, E. R.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save

Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL) (CheckMate 067)

Meeting Abstract

Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Cowey, C. L.; Lao, C. D.; Wagstaff, J.; Hogg, D.; Hill, A.; Carlino, M. S.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save

A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma

Meeting Abstract

van Herpen, C.; Postow, M. A.; Carlino, M. S.; Kalkavan, H.; Weise, A.; Amaria, R. N.; De Vos, F.; Carvajal, R. D.; Matano, A.; Bhansali, S.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save

Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial

Meeting Abstract

Soria, J. C.; Goldman, J. W.; Wakelee, H.; Gadgeel, S.; Camidge, D. R.; Solomon, B.; Yu, H.; Oxnard, G. R.; Ou, S. H.; Papadimitrakopoulou, V.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save

Rociletinib treatment and outcomes in non-small cell lung cancer (NSCLC) patients with negative central testing for T790M

Meeting Abstract

Solomon, B.; Wakelee, H.; Sequist, L. V.; Gadgeel, S.; Soria, J. C.; Goldman, J. W.; Yu, H.; Camidge, D. R.; Papadimitrakopoulou, V.; Matheny, S.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save